Metraipolis › archive › dc_fa2ebc5f1e4a

Cost-effectiveness of lenvatinib plus pembrolizumab as the second-line treatment for advanced endometrial carcinoma — Europe PMC PMID:41535916

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41535916
DOI
10.1186/s12962-[numero omesso]-y
License (as archived)
solo-consultazione
Archived
2026-11-06T20:02:38.171Z
SHA-256 of the archived text
fa5a3ddcb3fc6e216737a94f9d17b4408dfa569559d0ccb05e5b51f0e91158a6
Stable URL of this page
https://metraipolis.com/documento/dc_fa2ebc5f1e4a

How to cite

Cost-effectiveness of lenvatinib plus pembrolizumab as the second-line treatment for advanced endometrial carcinoma — Europe PMC PMID:41535916 — Europe PMC (en), https://europepmc.org/article/MED/41535916 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_fa2ebc5f1e4a (Metraipolis archive dc_fa2ebc5f1e4a, sha256 fa5a3ddcb3fc6e216737a94f9d17b4408dfa569559d0ccb05e5b51f0e91158a6)
BibTeX
@misc{dcfa2ebc5f1e4a,
  title = {Cost-effectiveness of lenvatinib plus pembrolizumab as the second-line treatment for advanced endometrial carcinoma — Europe PMC PMID:41535916},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41535916},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_fa2ebc5f1e4a; sha256 fa5a3ddcb3fc6e216737a94f9d17b4408dfa569559d0ccb05e5b51f0e91158a6},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41535916. Agents can read the archived copy with the MCP tool read_document.